Edition:
United Kingdom

Radius Health Inc (RDUS.OQ)

RDUS.OQ on NASDAQ Stock Exchange Global Market

30.54USD
22 Jun 2018
Change (% chg)

$-0.53 (-1.71%)
Prev Close
$31.07
Open
$31.05
Day's High
$31.54
Day's Low
$30.06
Volume
502,883
Avg. Vol
251,435
52-wk High
$49.15
52-wk Low
$24.68

Chart for

About

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosi... (more)

Overall

Beta: 1.31
Market Cap(Mil.): $1,686.22
Shares Outstanding(Mil.): 43.50
Dividend: --
Yield (%): --

Financials

  RDUS.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -5.19 -- --
ROI: -75.07 2.00 14.38
ROE: -75.11 3.49 16.08

BRIEF-Radius Health Reports Q1 Loss Per Share Of $1.37

* RADIUS HEALTH REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

10 May 2018

BRIEF-Radius Health Initiates Phase 3 Trial Of Abaloparatide Injection For Male Osteoporosis

* RADIUS HEALTH INITIATES PHASE 3 CLINICAL TRIAL OF ABALOPARATIDE INJECTION FOR THE TREATMENT OF MALE OSTEOPOROSIS Source text for Eikon: Further company coverage:

30 Mar 2018

BRIEF-Radius Health Provides Update On CHMP Opinion For Abaloparatide-SC

* RADIUS HEALTH PROVIDES UPDATE ON CHMP OPINION FOR ABALOPARATIDE-SC

22 Mar 2018

BRIEF-Radius Health Reports Q4 Loss Per Share $1.59

* RADIUS HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

01 Mar 2018

Earnings vs. Estimates